Skip to main navigation Skip to search Skip to main content

An Open-Label, Phase 1b/2a Study to Evaluate the Safety and Tolerability of Oral SVG103 (paxalisib) in Adults with Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME), Followed by Long-Term Treatment

Project: Research

Project Details

StatusActive
Effective start/end date19/03/26 → 18/03/28

Keywords

  • clinical trials
  • Focal Cortical Dysplasia
  • Hemimegalencephaly
  • Oral SVG103 (paxalisib)

Clinical Trial Phase

  • Phase I
  • Phase II
  • External Sponsor